WHO ICTRP trial
A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin…
IRCT20200525047570N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20200525047570N1 |
|---|---|
| Public title | A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm |
| Scientific title | A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm |
| Primary sponsor | Tabriz University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Covid-19. Covid-19 disease;U07.1 |
| Interventions | Intervention 1: Intervention Group 1 receives Tocilizumab? Vial, a humanized antibody, and an interleukin 6 receptor. A dose of 162mg/0.9ml will be administered once a week Subconsciously for two weeks. Currently, no specific manufacturer… |
| Registration date | Jul 30, 2020 |
| Target size | 60 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: